Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Another important step toward a prophylactic vaccine against hepatitis C.

Hepatology (Baltimore, Md.)·2022

Same author

SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals.

Nature microbiology·2022

Same author

Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection.

Current opinion in gastroenterology·2022

Same author

SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis.

Journal of hepatology·2022

Same author

[Autoimmune diseases of the gastrointestinal tract].

Deutsche medizinische Wochenschrift (1946)·2022

Same author

[Autoimmune Hepatitis - What is important for clinical practice?]

Deutsche medizinische Wochenschrift (1946)·2022

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Targeted therapy for hepatocellular carcinoma.

Hans Christian Spangenberg¹, Robert Thimme, Hubert E Blum

¹Department of Medicine II, University of Freiburg, Freiburg, Germany.

Nature Reviews. Gastroenterology & Hepatology

|June 3, 2009

Summary

Targeted therapies, like sorafenib, offer new hope for advanced hepatocellular carcinoma (HCC) patients. Despite progress in early detection, survival rates for liver cancer remain poor, highlighting the need for effective treatments.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 22, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

Oncology
Hepatology
Molecular Biology

Background:

Hepatocellular carcinoma (HCC) is a prevalent global malignancy with well-defined risk factors.
Despite advances in early detection, patient survival for HCC has stagnated over the past 30 years.
Limited therapeutic options exist for the majority of patients presenting with advanced or multifocal HCC.

Purpose of the Study:

To review the mechanisms of targeted therapies in HCC treatment.
To discuss clinical studies evaluating targeted therapies for HCC.
To provide perspectives on future developments in HCC therapy.

Main Methods:

Literature review of targeted therapies in hepatocellular carcinoma.
Analysis of clinical trial data for HCC targeted treatments.
Discussion of molecular mechanisms underlying targeted therapy efficacy.

Main Results:

Targeted therapies, including monoclonal antibodies and kinase inhibitors, show efficacy in various tumors.
Sorafenib, a multitargeted kinase inhibitor, significantly prolonged survival in advanced HCC patients in 2007.
Current therapeutic strategies are insufficient for over 80% of HCC patients diagnosed with advanced disease or comorbidities.

Conclusions:

Targeted therapies represent a significant advancement in managing advanced HCC.
Further research into novel targeted agents and treatment combinations is crucial for improving HCC patient outcomes.
The development of targeted therapies offers new hope for patients with limited treatment options.